Good
Mostly Aligned
Patient Risk:
Low
Summary
Most statements are broadly consistent with the provided label excerpts (drug ingredient and lipid-risk context), but the cardiovascular-risk claim is not directly supported by the provided INDICATIONS AND USAGE text, and the generic-name statement is not a label-supported item in the supplied excerpts.
Category Scores
Accurate Statements
Atorvastatin calcium is the active ingredient in the drug class statins.
The provided label excerpt identifies LIPITOR as (atorvastatin calcium) with atorvastatin as the active lipid-lowering ingredient and describes the mechanism as HMG-CoA reductase inhibition (12).
Atorvastatin calcium is used to help lower cholesterol.
INDICATIONS AND USAGE and clinical pharmacology context indicate use of lipid-altering therapy and that LIPITOR is a synthetic lipid-lowering agent (INDICATIONS AND USAGE; 12 Clinical Pharmacology).
Atorvastatin calcium is used to lower cardiovascular risk.
INDICATIONS AND USAGE includes therapy for individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia, and the provided snippet text discusses starting therapy in patients with CHD or multiple risk factors (INDICATIONS AND USAGE).
Unsupported Statements
The generic name of atorvastatin calcium is atorvastatin calcium.
The supplied label excerpts do not include a statement about the generic name or that 'atorvastatin calcium' is the generic name of 'atorvastatin calcium.'
Contradictions
Important Omissions
None material to the specific evaluation since the claims list contains only ingredient/name and broad indication/risk statements; no dosing, contraindications, warnings, interactions, populations, or adverse reactions were claimed.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The evaluated claims are limited to ingredient/class and general lipid/cardiovascular risk framing. No dosing, contraindications, warnings, or monitoring instructions were asserted, and the only clearly unsupported item was the generic-name phrasing.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
One statement (generic-name wording) is not supported by the provided labeling excerpts.
Suggested Improvement
Remove or rephrase the generic-name claim to rely on labeling-supported terminology; keep only label-supported indication/lipid-risk language from INDICATIONS AND USAGE.